What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several year...
Main Authors: | Testa, L, Bhindi, R, Van Gaal, W, Latini, R, Pizzocri, S, Lanotte, S, Biondi Zoccai, G, Valgimigli, M, Laudisa, M, Brambilla, N, Banning, A, Bedogni, F |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2010
|
Registos relacionados
-
Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis.
Por: Testa, L, et al.
Publicado em: (2010) -
Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents
Por: L. Testa, et al.
Publicado em: (2010-01-01) -
Use of prasugrel in patients with clopidogrel hypersensitivity
Por: Aparna Joshi, et al.
Publicado em: (2022-01-01) -
Interaction between statins and clopidogrel: is there anything clinically relevant?
Por: Bhindi, R, et al.
Publicado em: (2008) -
Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
Por: Satoshi Niijima, et al.
Publicado em: (2018-03-01)